Searched over 200M research papers
10 papers analyzed
These studies suggest that lisinopril is an effective and well-tolerated treatment for heart failure, improving exercise duration, quality of life, and heart failure symptoms, with some studies indicating it may be superior to captopril, while other studies suggest omapatrilat may have advantages over lisinopril.
20 papers analyzed
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used in the management of heart failure. This article synthesizes findings from multiple studies to evaluate the efficacy, optimal dosage, and comparative effectiveness of lisinopril in treating heart failure.
Lisinopril has been shown to significantly improve exercise tolerance and cardiac function in patients with heart failure. In a study comparing lisinopril to placebo, patients receiving lisinopril exhibited notable improvements in treadmill exercise time, ejection fraction, and overall functional status . Additionally, lisinopril increased left ventricular ejection fraction in patients with moderately to severely decreased function .
High doses of lisinopril (32.5 to 35 mg daily) have been associated with a significant reduction in hospitalizations for heart failure and a lower risk of death or hospitalization for any reason compared to low doses (2.5 to 5.0 mg daily). This suggests that higher doses of lisinopril may offer greater benefits in reducing morbidity and mortality in heart failure patients.
The ATLAS study highlighted that while high doses of lisinopril significantly reduced hospitalizations and combined endpoints of death or hospitalization, the difference in mortality alone was not statistically significant. This indicates that while higher doses may be more effective in reducing hospitalizations, the impact on mortality may be less pronounced.
Lisinopril, administered once daily, has been compared to captopril, a shorter-acting ACE inhibitor taken multiple times a day. Studies have shown that once-daily lisinopril is at least as effective as captopril in improving exercise tolerance and left ventricular ejection fraction . This once-daily regimen may offer better compliance and convenience for patients.
Multiple studies have compared lisinopril to captopril in heart failure treatment. Lisinopril was found to be superior in improving exercise duration, particularly in patients with renal impairment . Both drugs were well tolerated, with no significant differences in adverse effects .
In a study comparing lisinopril to omapatrilat, a vasopeptidase inhibitor, both drugs showed similar improvements in exercise tolerance. However, omapatrilat was associated with fewer cardiovascular adverse events and a trend towards better outcomes in terms of death or hospitalization for worsening heart failure. This suggests that while lisinopril is effective, newer agents like omapatrilat may offer additional benefits.
Lisinopril has been shown to be effective and well-tolerated in elderly patients with heart failure, providing similar improvements in exercise tolerance and cardiac function as seen in younger patients . This makes lisinopril a viable option for older adults with heart failure.
In patients with heart failure and chronic atrial fibrillation, lisinopril improved peak oxygen consumption and showed a trend towards better left ventricular function. This indicates that lisinopril may be particularly beneficial in this subgroup due to its antiadrenergic properties.
Lisinopril is a highly effective ACE inhibitor for the treatment of heart failure, improving exercise tolerance, cardiac function, and reducing hospitalizations. Higher doses may offer additional benefits, particularly in reducing hospitalizations, though the impact on mortality alone is less clear. Comparative studies suggest that lisinopril is at least as effective as captopril and may be preferable due to its once-daily dosing. Additionally, lisinopril is effective in both elderly patients and those with atrial fibrillation, making it a versatile option in heart failure management.
Most relevant research papers on this topic